Dr Reddy's launch generic Zoledronic Acid injection in the US

The injection is used for treating osteoporosis and Paget's disease of bone.


New Delhi, April 4, 2013: Dr Reddy’s today said that after securing the approval from the US drug and health regulator, the company has launched the generic version of Zoledronic Acid injection used for treating osteoporosis and Paget's disease of bone in the US market.


It may be noted here that the company said in a statement that it has launched Zoledronic Acid injection (5 mg/ 100 mL), following approval of its abbreviated new drug application (ANDA) by the US Food & Drug Administration (USFDA).


The company also added that the product is the generic version of Novartis’ Reclast injection in the same strength.


Going by the claim of the Indian company, Reclast brand had total US sales of approximately USD 355 million for the most recent twelve months ending February, 2013.


* Indicates mandatory field.
Please wait while comments are being sent...